The Oncology Institute, Inc. Common Stock (TOI)
The Oncology Institute, Inc. (TOI) is a healthcare company focusing on providing specialized oncology care. It operates a network of outpatient clinics dedicated to the treatment of cancer, offering medical, radiation, and infusion services. The company emphasizes patient-centered care through a comprehensive approach, integrating advanced treatment options with supportive services.
Company News
The Oncology Institute reported Q2 2025 revenue of $119.8 million, a 21.5% year-over-year increase, driven by strong pharmacy segment performance. Despite revenue growth, the company continues to face challenges with net losses and cash burn.
The Oncology Institute, Inc. (TOI) announced a $16.5 million private placement with existing investors, management, and directors. The proceeds will be used for organic growth and working capital. The company also entered an exchange agreement with Deerfield Management Company to exchange convertible notes for preferred stock and warrants.
The Oncology Institute (TOI) delivered earnings and revenue surprises of -83.33% and 0.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
As of Jan. 8, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. Harpoon Therapeutics, Inc. (NASDAQ:
Are these penny stocks a buy before next year? The post Penny Stocks To Buy Now? 4 To Watch Before 2024 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.